Loading...
•
Mar 31, 2022
PDS Biotechnology Q1 2022 Earnings Report
PDS Biotechnology reported a net loss and increased R&D expenses compared to the same quarter last year.
Key Takeaways
PDS Biotechnology reported a net loss of $8.5 million, or $0.32 per share, for the first quarter of 2022. Research and development expenses increased to $5.2 million, and the company's cash balance as of March 31, 2022, was $58.9 million.
Net loss was $8.5 million, or $0.32 per share.
Research and development expenses increased to $5.2 million.
General and administrative expenses increased to $3.3 million.
Cash balance as of March 31, 2022, was $58.9 million.
Forward Guidance
PDS Biotech projects its current cash balance to fund operations into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...